MoonLake Immunotherapeutics (MLTX) CMD 2025 summary

Strategic and Clinical Program Updates

• Advancing sonelokimab (SLK), a tri-specific Nanobody, in dermatology and rheumatology, with lead indications in hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP), and additional trials in PsA, axSpA, and adolescent HS.

• VELA phase III in HS completed recruitment of 800 patients in ~12 months, about double the speed of competitors, with primary endpoint data expected in September 2025.

• Baseline characteristics in VELA-1 and VELA-2 closely match prior pivotal phase II (MIRA), supporting high confidence in replicating efficacy, with low dropout rates.

• PPP (LEDA) phase II trial fully enrolled ahead of schedule, with interim data showing strong biomarker and clinical responses, supporting rapid progression to phase III.

• Expansion into additional indications and adolescent trials aims to build a pipeline-in-a-product and de-risk the molecule.

Competitive Differentiation and Market Opportunity

• SLK aims to set a new gold standard in HS by targeting a HiSCR75 delta to placebo at week 16 that starts with a two, based on prescriber feedback and market needs.

• Differentiation includes higher efficacy, faster induction (8 weeks vs. 16 for competitors), fewer injections, and a favorable safety profile without label warnings seen in competitors.

• HS market projected to reach $10–15bn by 2035, with only ~3% biologics penetration and 2.5 million diagnosed US patients, representing significant growth potential.

• Most market growth is expected from bio-naive and refractory patients, not switches, with prescribers highly concentrated.

• PPP represents a $3–4 billion opportunity by 2038, with no approved treatments and strong early data for SLK.

Financial Position and Commercialization Plans

• Secured a $500 million non-dilutive facility with Hercules Capital, providing flexibility and extending cash runway into 2028.

• Ended Q1 with $547 million in cash and equivalents, eliminating perceived financing overhang and supporting manufacturing scale-up and commercial ramp-up.

• Commercial focus is on the US, with preparations for a physical presence and payer engagement underway; ex-US partnerships remain an option.

• Manufacturing is currently in Europe, with plans to add a second source and expand capacity as needed.

• Financial strategy prioritizes shareholder value by avoiding dilution at current share prices and leveraging competitive cost of capital.